AH:CA:TSX-Aleafia Health Inc (CAD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | TSX

Last Closing Price

CAD 0.39

Change

-0.01 (-1.28)%

Market Cap

CAD 0.13B

Volume

0.14M

Avg Analyst Target

CAD 1.00 (+159.74%)

Avg User Target

CAD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Aleafia Health Inc. operates as an integrated cannabis health and wellness services company in Canada and internationally. It produces a portfolio of products, including dried flower and pre-rolls, as well as oil drops and capsules, oral sprays, and cannabis-infused sublingual strips. The company offers its products under the Kin Slips, Emblem, and Symbl brands. It also operates a network of 25 medical cannabis clinics under the Canabo Clinics brand name; and education centers. The company was incorporated in 2007 and is headquartered in Concord, Canada.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-07-22 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
BHC:CA Bausch Health Companies Inc

-0.52 (-1.43%)

CAD13.05B N/A 21.78
WEED:CA Canopy Growth Corporation

-0.76 (-2.96%)

CAD10.07B N/A N/A
APHA:CA Aphria Inc

N/A

CAD4.44B 57.08 598.01
CRON:CA Cronos Group Inc

-0.30 (-3.20%)

CAD3.45B 46.76 N/A
ACB:CA Aurora Cannabis Inc

-0.41 (-4.34%)

CAD1.87B 1,171.00 N/A
OGI:CA OrganiGram Holdings Inc

-0.15 (-4.56%)

CAD0.98B -99,999.99 N/A
HEXO:CA HEXO Corp

-0.27 (-4.82%)

CAD0.84B N/A N/A
GUD:CA Knight Therapeutics Inc

+0.04 (+0.78%)

CAD0.64B 14.09 3.23
CWEB:CA Charlotte's Web Holdings, Inc

-0.08 (-1.92%)

CAD0.55B 120.37 N/A
HLS:CA HLS Therapeutics Inc

+0.01 (+0.06%)

CAD0.55B N/A 35.22

ETFs Containing AH:CA

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -18.09% 20% F 7% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -18.09% 20% F 7% F
Trailing 12 Months  
Capital Gain -32.46% 20% F 5% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -32.46% 20% F 5% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -0.53% 40% F 21% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -0.53% 40% F 15% F
Risk Return Profile  
Volatility (Standard Deviation) 3.63% 96% A 93% A
Risk Adjusted Return -14.59% 40% F 11% F
Market Capitalization 0.13B 46% F 36% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio -99,999.99 75% C 98% A+
Price/Book Ratio 0.76 93% A 88% B+
Price / Cash Flow Ratio -16.89 75% C 88% B+
EV/EBITDA 45.67 23% F 10% F
Management Effectiveness  
Return on Equity -92.55% 32% F 7% F
Return on Invested Capital -13.32% 57% F 14% F
Return on Assets -9.68% 44% F 10% F
Debt to Equity Ratio 21.04% 50% F 72% C-
Technical Ratios  
Short Ratio 3.70 57% F 29% F
Short Percent 0.36% 63% D 71% C-
Beta 1.27 65% D 35% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector